Therapeutics targeting persistent inflammation in chronic kidney disease

Machowska, Anna; Carrero, Juan Jesús; Lindholm, Bengt; Stenvinkel, Peter

doi:10.1016/j.trsl.2015.06.012

Cited by 101 publications

(80 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…102 These data create hopes that blocking IL-1-driven systemic inflammation could improve nutritional status and body wasting, and eventually dampen accelerated cardiovascular disease in ESRD. 103 A trial with monoclonal anti-IL-1b IgG gevokizumab in diabetic kidney disease is ongoing. 104 Clinical trials testing whether IL-1 blockade can also improve outcomes in diseases such as GN, vasculitis, or AKI are still awaited.…”

Section: Il-1-related Drugs and Clinical Datamentioning

confidence: 99%

Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease

Anders

2016

JASN

204

152

View full text Add to dashboard Cite

Kidney injury implies danger signaling and a response by the immune system. The inflammasome is a central danger recognition platform that triggers local and systemic inflammation. In immune cells, inflammasome activation causes the release of mature IL-1b and of the alarmin IL-1a. Dying cells release IL-1a also, independently of the inflammasome. Both IL-1a and IL-1b ligate the same IL-1 receptor (IL-1R) that is present on nearly all cells inside and outside the kidney, further amplifying cytokine and chemokine release. Thus, the inflammasome-IL-1a/IL-b-IL-1R system is a central element of kidney inflammation and the systemic consequences. Seminal discoveries of recent years have expanded this central paradigm of inflammation. This review gives an overview of arising concepts of inflammasome and IL-1a/b regulation in renal cells and in experimental kidney disease models. There is a pipeline of compounds that can interfere with the inflammasome-IL-1a/IL-b-IL-1R system, ranging from recently described small molecule inhibitors of NLRP3, a component of the inflammasome complex, to regulatory agency-approved IL-1-neutralizing biologic drugs. Based on strong theoretic and experimental rationale, the potential therapeutic benefits of using such compounds to block the inflammasome-IL-1a/IL-b-IL-1R system in kidney disease should be further explored.

show abstract

Section: Il-1-related Drugs and Clinical Datamentioning

confidence: 99%

Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease

Anders

2016

JASN

204

152

View full text Add to dashboard Cite

show abstract

“…Additionally, continued oxidative stress can trigger the infiltration of inflammatory mediators which in turn can lead to inflammation of affected tissue. Persistence of inflammation can further exacerbate the oxidative stress induced complications (Machowska et al, 2015;Martinon, 2010). Previous studies have implicated the oxidative stress and inflammation as major cellular changes promoting kidney damage.…”

Section: Discussionmentioning

confidence: 99%

Deleterious effects of incense smoke exposure on kidney function and architecture in male albino rats

Hussain¹,

Al‐Attas²,

Alrokayan³

et al. 2016

Inhalation Toxicology

View full text Add to dashboard Cite

show abstract

“…Las concentraciones séricas de LPS se incrementan en presencia de infección, y en ausencia de ésta, las concentraciones elevadas (endotoxemia) se asocian a una translocación bacteriana incrementada, a consecuencia de disfunción intestinal. La endotoxemia ha sido ampliamente descrita en pacientes urémicos con ERC, asociándose a la presencia de infecciones recurrentes en los catéteres en pacientes bajo tratamiento renal sustitutivo, a periodontitis, a la contaminación de las soluciones dializantes, al estado de sobrehidratación, y recientemente a las alteraciones en las uniones estrechas intestinales [7][8][9][10] .…”

Section: Introductionunclassified

Alteraciones en el eje intestino-riñón durante la enfermedad renal crónica: causas, consecuencias y propuestas de tratamiento

Osuna-Padilla

Leal-Escobar

2017

Rev Esp Nutr Hum Diet

View full text Add to dashboard Cite

La enfermedad renal crónica y el estado urémico se asocian con alteraciones en la permeabilidad intestinal y cambios en la microbiota intestinal, provocando una mayor producción y translocación de toxinas urémicas como sulfato de indoxilo (IS) y sulfato de p-cresilo (pCS), detonando una respuesta inflamatoria. El estado inflamatorio y el incremento en concentraciones séricas de IS y pCS se han asociado con una mayor mortalidad, mayor número de eventos cardiovasculares y mayores alteraciones en el metabolismo mineral y óseo. Se han estudiado diversas estrategias nutricionales y farmacológicas para modular la microbiota intestinal y mejorar las alteraciones en la permeabilidad intestinal, entre ellas la suplementación con probióticos, prebióticos y simbióticos, modificaciones en la composición de la dieta y uso de agentes adsorbentes. El objetivo del presente trabajo es realizar una revisión de las causas de las alteraciones intestinales y de la microbiota intestinal en el paciente con enfermedad renal crónica, analizando las consecuencias de dichos cambios y las intervenciones estudiadas hasta la actualidad. PALABRAS CLAVE R E S U M E NAlteraciones en el eje intestino-riñón durante la enfermedad renal crónica: causas, consecuencias y propuestas de tratamiento

show abstract

Therapeutics targeting persistent inflammation in chronic kidney disease

Cited by 101 publications

References 90 publications

Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease

Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease

Deleterious effects of incense smoke exposure on kidney function and architecture in male albino rats

Alteraciones en el eje intestino-riñón durante la enfermedad renal crónica: causas, consecuencias y propuestas de tratamiento

Contact Info

Product

Resources

About